Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE‐1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myeloma-Reference-Cited by-同舟云学术

Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE‐1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myeloma

Published:2021-12-10 Issue:1 Volume:3 Page:97-108
ISSN:2688-6146
Container-title:eJHaem
language:en
Short-container-title:eJHaem

Author:

Martin Thomas¹,Krishnan Amrita²,Yong Kwee³,Weisel Katja⁴,Mehra Maneesha⁵,Nair Sandhya⁶,Qi Keqin⁷,Londhe Anil⁷,Diels Joris⁶,Crivera Concetta⁸,Jackson Carolyn C.⁹,Olyslager Yunsi⁶,Vogel Martin⁵,Schecter Jordan M.¹⁰,Banerjee Arnob¹⁰,Valluri Satish⁵^ORCID,Usmani Saad Z.⁹,Berdeja Jesus G.¹¹,Jagannath Sundar¹²

Affiliation:

1. UCSF Helen Diller Family Comprehensive Cancer Center San Francisco California USA

2. Judy and Bernard Briskin Center for Multiple Myeloma Research Duarte California USA

3. University College Hospital London UK

4. University Medical Center Hamburg‐Eppendorf Hamburg Germany

5. Janssen Global Services LLC Raritan New Jersey USA

6. Janssen Pharmaceutica NV Beerse Belgium

7. Janssen R&D LLC Titusville New Jersey USA

8. Janssen Scientific Affairs LLC Horsham Pennsylvania USA

9. Levine Cancer Institute‐Atrium Health Charlotte North Carolina USA

10. Janssen R&D Raritan New Jersey USA

11. Sarah Cannon Research Institute Nashville Tennessee USA

12. Mount Sinai Medical Center New York New York USA

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jha2.312

Reference24 articles.

1. Current treatment landscape for relapsed and/or refractory multiple myeloma

2. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy

3. Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management

4. MartinTG KrishnanAY YongK WeiselK MehraM NairS et al.Comparison of outcomes with ciltacabtagene autoleucel (cilta‐cel) in CARTITUDE‐1 versus real‐world standard of care (RW SOC) for patients (pts) with triple‐class exposed relapsed/refractory multiple myeloma (RRMM). Abstract #8045.Poster presented at American Society of Clinical Oncology (ASCO) Annual Meeting;2021Jun 4–8;Virtual.

5. WeiselKC MartinT YongK QiK LondheA&KobosRet al. Characteristics and treatment patterns of triple‐class exposed patients with relapsed/refractory multiple myeloma who participated in clinical trials of daratumumab. Oral presentation presented at 47th Annual Meeting of the European Society of Blood and Marrow Transplantation (EBMT); 2021 Mar 14–17.

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of CARVYKTI in CARTITUDE-4 versus other conventional treatment regimens for lenalidomide-refractory multiple myeloma using inverse probability of treatment weighting;Journal of Comparative Effectiveness Research;2024-09

2. Externally Controlled Studies Using Real-World Data in Patients With Hematological Cancers;JAMA Oncology;2024-08-29

3. Talquetamab Versus Real-World Physician's Choice Treatment: Comparative Effectiveness in Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma;Clinical Lymphoma Myeloma and Leukemia;2024-08

4. Examining external control arms in oncology: A scoping review of applications to date;Cancer Medicine;2024-07

5. The new era of immunological treatment, last updated and future consideration of CAR T cell-based drugs;Pharmacological Research;2024-05